EC
PRME icon

EcoR1 Capital’s Prime Medicine PRME Stock Holding History

EcoR1 Capital’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,543,326
Closed -$8.55M – 37
2025
Q3 		$8.55M Buy
+1,543,326
New +$6.27M 0.41% 23
2025
Q2 		– Sell
-700,000
Closed -$1.39M – 44
2025
Q1 		$1.39M Hold
700,000
– – 0.08% 40
2024
Q4 		$2.04M Hold
700,000
– – 0.08% 52
2024
Q3 		$2.71M Hold
700,000
– – 0.09% 53
2024
Q2 		$3.6M Hold
700,000
– – 0.11% 47
2024
Q1 		$4.9M Buy
+700,000
New +$5.31M 0.12% 52
2023
Q4 		– Sell
-600,000
Closed -$5.72M – 55
2023
Q3 		$5.72M Hold
600,000
– – 0.19% 39
2023
Q2 		$8.79M Hold
600,000
– – 0.22% 36
2023
Q1 		$7.38M Hold
600,000
– – 0.24% 36
2022
Q4 		$11.1M Buy
+600,000
New +$10.8M 0.34% 36

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

EcoR1 Capital's PRME Position: Q4 2025 in Review

EcoR1 Capital sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 1,543,326 shares — an estimated $8.55M sold.

EcoR1 Capital first reported a position in PRME in Q4 2022 and held it in 10 quarters. The position peaked at $11.1M in Q4 2022. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • EcoR1 Capital reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • EcoR1 Capital sold 1,543,326 Prime Medicine shares in Q4 2025, an estimated $8.55M.
  • EcoR1 Capital first reported a position in Prime Medicine in Q4 2022 and held it in 10 quarters.
  • EcoR1 Capital's Prime Medicine position peaked at $11.1M in Q4 2022.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on EcoR1 Capital's 13F filing for Q4 2025, filed 17 Feb 2026.